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Host leukemic cells of 3 patients were recognized by MiHAspecific TCL in a chromium release assay and in one experiment host leukemic cells were effectively killed and their growth specifically inhibited in a leukemia colony assay by a clone. These data demonstrate that (1) host-specific cytotoxic TCL are detected exclusively in the PB of patients with acute GVHD grades II through IV after allogeneic matched bone marrow transplantation, and (2) their target antigens are simultaneously expressed on several host cell lines, including lymphoblastoid cell lines, PHA blasts, leukemic cells, and K. We also extend previous findings by showing that, besides the expression of the nominal MiHA, the density of the restricting class I MHC elements also crucially determines the extent of TCL lysis. Because of its capacity to enhance class I MHC antigen expression, IFN-7 represents a key cytokine for determining the susceptibility of MiHA targets for lysis by TCL and clones, and in one patient an MiHA-specific clone recognized host leukemic cells and also inhibited host leukemic cell growth in a colony inhibition assay.
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Molecules associated with the male-specific H-Y antigen were described as MiHA in h u m a r~s .~~. *~ Recent experiments indicate that MiHA are peptides from endogeneous cell proteins that bind to MHC and are recognized by the antigen-binding T-cell receptors. 13322, [24] [25] [26] [27] This study was aimed at isolating host-specific T-cell lines (TCL) from the blood stream of patients who underwent MHC-identical allogeneic BMT, and to correlate their occurrence with clinical expression of GVHD. Also investigated were the tissue distribution of MiHA, the patterns of MHC restriction of host-reactive TCL lysis, and their interaction with GVHD targets of epithelial or leukemic origin.
PATIENTS AND METHODS
Patients. Seventeen (1 I male and 6 female) patients undergoing BMT from their HLA-identical and MLC-negative sibling donors for treatment of hematologic malignancies (acute myelogenous leukemia [n = 41; acute lymphoblastic leukemia [n = 21; lymphoma [n = 41; myelodysplastic syndrome [n = I]; and chronic myelogenous leukemia [n = 41) and severe aplastic anemia (n = 2) were investigated. Clinical characteristics ofthese patients are given in Table I . Patients with hematologic malignancies were conditioned with cyclophosphamide (2 X 60 mg/kg/d) and total body irradiation (either as single dose 10 Gy or fractionated 2 X 2 Gy/d on 3 consecutive days), whereas patients with severe aplastic anemia (n = 2) were pretreated with cyclophosphamide 50 mg/kg/d for 4 days. One patient with lymphoma (unique patient number [UPN] 57) received cannustin (BCNU), etoposide (VP-16), and cyclophosphamide without irradiation before BMT. Cyclosporin was used as GVHD prophylaxis either alone (n = 14)" or in combination with methotrexate (n = 3).29 Nine of the 17 patients developed GVHD grades I1 through IV and were subsequently treated with high-dose methylprednisolone ( Table 1) .
Isolation of peripheral blood mononuclear cells (PBMC). Heparinized PB was taken from donors before BM harvest, from patients before transplantation and during GVHD, or, at the latest, 2 months after BMT. PBMC were separated on Ficoll-Isopaque (Lymphoprep, Nyegard, Norway), washed three times, frozen, and stored in liquid nitrogen.
Pretransplantation recipient PBMC were resuspended in tissue culture medium at concentrations of 2 X 106/mL and mixed with the same amount of a mycoplasma-free EBV producer line B 95-8 supernatant and 200 np/ mL cyclosporin (Sandimmun; Sandoz, Vienna, Austria). On day 6 and every third day thereafter, 50% of the culture medium was replaced by fresh medium. Cyclosporin was added to the culture until the third week.
PBMC (1 X 106/mL) from the host or donor were incubated with I% PHA (Difco, Detroit, MI) in a humidified 5% C02/95% air atmosphere at 37°C for 72 hours. For further growth, cells were cultured in 20 U/mL recombinant IL-2 (Hoffmann-LaRoche, Basel, Switzerland).
TCL were established from 2 X 106/mL posttransplant recipient PBMC harvested during GVHD or, in the absence of GVHD, at the latest 2 months after BMT, stimulated with 2 X 106/mL irradiated (30 Gy) pretransplant recipient PBMC, and cultured in RPMI 1640 (Biochrom, Berlin, Germany) medium containing 100 U/mL penicillin (Biochemie, Vienna, Austria) and 20 pg/mL gentamicin (Biochemie) supplemented with 15% human male AB pool serum. On day 6, cells were placed in fresh culture medium (2 x io5 celk/mL), restimulated with 4 x 1 o S / m~ irradiated (50 Gy) EBV-transformed, pretransplant recipient PBMC, supplemented with 15% pool serum and 2% Lymphocult-Highly Purified ( H P Biotest, Frankfurt, Germany) as an interleukin-2 (IL2) source, and plated in a 24-well Costar plate (2 mL/well). Every third day, 50% of the medium was replaced with fresh medium and 20% of Lymphocult-T (Biotest) final concentration added to the culture. On day 14, cells were counted, adjusted to 2 X 105/mL responder cells, and restimulated with 2 X lo5 irradiated (50 Gy) EBV-transformed pretransplant recipient PBMC and 2 X IO6 donor cells/mL as feeder cells supplemented with 20% final concentration Lymphocult-T (Biotest). The cells were fed every other day and restimulated weekly with the same cell mixture as on day 14. TCL obtained after 3 weeks were used as polyclonal effector cells in cytotoxic assays. (30 Gy) stimulator pool of at least four healthy blood donors matching the TCL in one HLA-antigen and 10,000 irradiated (50 Cy) EBV-transformed recipient pretransplant cells/well. Finally, 20 U/mL recombinant IL-2 (Hoffmann-"he) and I% PHA-M (Difco) were added to the culture. After 6 days of culture, host-specific cytotoxic clones were selected and further cultured as described above. All clones and TCL were tested routinely for mycoplasma contamination (Gen-Probe; Gen-Probe Inc, San Diego, CA) and were negative.
K were obtained from donors and patients pretransplant using a keratotome. After washing, the cells were treated overnight with trypsin-EDTA (Biochrom) at 2°C. Epidermal cells (EC) were frozen and stored in liquid nitrogen or expanded as previously described.30 Briefly, 2 X IO6 fresh EC were plated in 75-cm2 flasks (Falcon; Becton Dickinson) containing 1.8 X lo6 irradiated (60 Gy) 3T3 feeder cells (a generous gift of Dr H. Green, Harvard University, Boston, MA). Cultures were kept in a 3: 1 mixture of Dulbecco Vogt modification of Eagle's medium in Ham's F 12 medium (Flow Laboratories, Irvine, UK) supplemented with 10% fetal calf serum (FCS Flow), 5 pg/mL insulin (Sigma, Munich, Germany), 2 X mol/L triiodo-L-thyronine (Serva, Heidelberg, Germany), IO-" mol/L choleratoxin (Calbiochem-Behring, La Jolla, CA), 5 pg/mL transferrin (Calbiochem-Behring), 0.4 &mL hydrocortisone (Calbiochem-Behring), and 8 X mol/L adenine (Boehringer Mannheim, Vienna, Austria). The cultures were incubated at 37°C in a 10% co2/90% air atmosphere and, after 2 days of culture, human recombinant epidermal growth factor (a generous gift of Dr George Nascimento, Chiron Corp, Emeryville, CA) was added at a final concentration of 10 ng/mL. Medium was changed three times weekly until K were confluent. For further expansion, K were subcultivated as described above. K of these secondary cultures were used as targets after incubation with human recombinant interferon-y (rIFN-y; Genentech, South San Francisco, CA; specific activity, 2 X lo7 IU/mg protein) or human rIFN-a2 (Boehringer Ingelheim, Ingelheim, Germany; specific activity, 3.2 X lo8 IU/mg protein) for 72 hours with concentrations ranging from 1 to 1,000
Isolation and culture of keratinocytes (K).
For personal use only. on August 30, 2017 . by guest www.bloodjournal.org From 2202 NIEDERWIESER ET AL U/mL. Choleratoxin was not included in culture media during incubation with IFN, as it prevents IFN from binding to its re~eptor.~' IFN-treated and untreated adherent K were recovered by treatment with 20 mL trypsin-EDTA for 30 minutes at 37°C and thereafter resuspended in RPMI medium supplemented with 15% heat-inactivated pool serum. The cells were washed, counted, adjusted to 1 X IO6 cells/mL, and used as targets in cytotoxic assays.
Isolation of chronic myelogenous leukemia (CML) cells and testing in soft agar colony assay.
Leukemic mononuclear blood cells were collected from three BMT recipients with CML and cryopreserved. Cryopreserved cells were thawed for 1 minute at 37°C in a water bath, washed three times, and resuspended in culture medium. CML cells from the recipients and, as controls, from unrelated patients were used as targets in a conventional 4-hour Cr release assay as described below and in a leukemia colony inhibition assay as previously described by Mackinnon et aL3' In this assay, target cells were preincubated in liquid culture without effector cells or with irradiated (5 Gy) TCL clones at an effector:target (E:T) ratio of 1O:l for 18 hours and subsequently cultured in triplicate for colony-forming units granulocyte-macrophage (CFU-GM) in an agar culture system as previously described.33 CFU-GM colonies were defined as granulocytic, monocytic, or mixed aggregates containing more than 50 cells. They were scored under an inverted microscope on day 14. The number of colonies cultured from lo5 CML cells in the absence of the TCL was considered 100%.
cml assays were performed as previously described. 34 In short, 1 X IO6 target cells (both donor and recipient K, PHA blasts, lymphoblastoid cell lines, recipient and third-party leukemia cells) were labeled with 100 pCi Nas1Cr04 (NEN, Dreieich, Germany; specific activity, 300 to 500 Ci/g chromate) for 120 minutes at 37°C. On average, the following labeling intensities were achieved: for lymphoblastoid cell lines, I .8 4 
Cell-mediated lympholysis (cml) assay.
Experimental Release -Spontaneous Release Maximum Release -Spontaneous Release
Experimental release represents cpm released from target cells in the presence of effector cells; spontaneous release is that from targets cultivated without effectors; and maximum release is cpm released from target cells after 4 hours of incubation with 2% Triton X-100 (Sigma). For natural killing, large granular lymphocytes from healthy volunteers enriched on discontinuous Percoll gradients served as effector cells.35 They were incubated with 5'Cr-labeled IFN-y (1000 U/ mL)-treated or untreated K and, as a positive control, with the human NK-sensitive leukemia cell line NK 562 for 16 hours at E:T ratios ranging from 100: 1 to 12: 1. Culture system, labeling of the targets, and expression of the results were identical with those described above.
The following MoAbs were used: MAS 1532 (Seralab, Crawley Down, Sussex, UK) and anti-HLA-DR (clone L243; Becton Dickinson) MoAb against common determinants on class I and class I1 MHC molecules, respectively. Also applied were MoAb VE 5 (anti-HLA-A 24), S 4 (anti-HLA-B 44), KT Quantification of MHC antigen expression by radioimmunoassay (RIA). MHC class I or class I1 antigen expression was determined by RIA as described by Greiner et aL3' One hundred microliters of RPMI 1640 (Biochrom) supplemented with 10% bovine serum albumin (BSA; Behring, Marburg, Germany) containing 5,000 cells was incubated per well of a 96-well tissue culture plate at 37°C for 1 hour. Thereafter, the plates were washed once with RPMI 1640 containing 1% BSA. Fifty microliters of MoAb (0.4 pg/mL) recognizing the nonpolymorphic determinants on HLA-DR (clone L243; Becton Dickinson) or on HLA-A,-B molecules (0.8 pg/mL; IOT-2 clone B 9.12.1; Immunotech, Marseille, France) was added to each well and incubated at 37°C for 1 hour. Subsequently, cells were washed twice using RPMI 1640 containing I% BSA and incubated with 50 pL of 1.6 pCi/mL 1Z51-labeled antimouse Ig F(ab), (Amersham, Buckinghamshire, UK; specific activity, 5 pCi/pg antibody protein) for 1 hour. The cells were washed three times and lysed, adding 100 pL of 2 N sodium hydroxide to each well. The resulting solution was absorbed with a cotton tip and analyzed in a gamma liquid scintillation counter (LKB). Background counts were determined using antimouse Ig F(ab'), (Amersham) only.
Student's t-test, X 2 test, and Wilcoxon matched pairs signed rank test were used to compute statistical differences.
Fluorescence-activated cell sorter (FACS) analysis.
Statistical evaluation.
RESULTS
Host-specific cytotoxic TCL are exclusively established
from patients with GVHD. PBMC isolated from 17 allogeneic BMT recipients after grafting were stimulated with irradiated pretransplant PBMC. Primary mixed leukocyte cultures (MLC) were then supplemented with natural IL-2 and restimulated with MiHAf lymphoblastoid cells derived from the respective recipient's pretransplant PBMC. Under these conditions and from a total of 59 TCL grown, cytotoxic TCL with specificity for host cells were exclusively obtained from those 9 patients presenting with grades I1 through IV GVHD. No such cytotoxic TCL were established in the 8 patients with GVHD grades 0 through 1. These differences were statistically significant (Table 2, P = .OOOl). TCL were tested for their capacity to lyse donor or host pretransplant PHA blasts. Lysis of all 9 TCL was restricted to host targets, as shown by resistance of the HLA-identical donor cells to lysis, and was therefore designated MiHA-specific (Table 2, P < .01). The possibility that cytotoxicity was directed against splits of MHC class I antigens was eliminated either by HLA typing of the parents or by biochemical HLA class I subtyping using a n isoelectric focusing method.
For x2 test.
t Lysis of TCL from PBMC of patients with GVHD grades Il-IV versus lysis of TCL from patients with GVHD grades 0-1 (Student's t-test) and MiHAspecific TCL lysis of host PHA targets versus donor PHA targets (Student's r-test).
FACS analysis of cytotoxic TCL with specificity for host cells showed a predominant CD8 positivity (79.9%) and only a low percentage (16.9%) of CD4+ cells (Table 3, UPN 53 ). In contrast, TCL without specificity for host cells were CD4+ (91.8%) and CD8- (Table 3 , UPN 58). All TCL expressed the CD3 marker and consistently lacked the CD16 (NK-cell associated) marker (Table 3) .
The two TCL UPN 37 and 53 were further cloned, and clones displaying host specificity were expanded for further testing. Host-specific cytotoxic clones also showed a CD3+, CD8+, CD16-, CD4-phenotype (Table 3, UPN 53 clone 7) and the noncytotoxic clones a CD3+, CD8-, CD 16-, CD4+ phenotype (Table 3, UPN 53 clone 2) .
Expression of MiHA on various hematopoietic and nonhematopoietic host targets. Cytotoxic TCL specific for MiHA were used to screen various hematopoietic and nonhematopoietic cells from the respective hosts for expression of MiHA. Lymphoblastoid cell lines, PHA blasts, leukemic cells, and K of host and of donor origin were used as targets. MMA, as defined by specific lysis, were detected on both hematopoietic and nonhematopoietic cells, but the amount of target cell killing was variable (Fig 1) . Host lymphoblastoid cell lines and PHA blasts were more susceptible to lysis than K and leukemic cells. Expression of MiHA on these targets was also confirmed by experiments with the two clones. An identical pattern with preferential lysis of host lymphoblastoid cells and PHA blasts was again observed (Fig 2) .
Class I MHC represents the restricting element of MiHAspecifrc TCL responses and its expression crucially controls target cell lysis.
Published evidence suggests that recognition of MiHA' targets by TCL is restricted by class I MHC antigens.24,25,38-42 0 ur MoAb blocking experiments also confirmed these findings (Fig 3) . Treatment with MoAb against common determinants of MHC class I but not class I1 antigens inhibited cytotoxicity. Blocking by MoAb against framework determinants of MHC class I antigens was more efficient than MoAb against polymorphic determinants of HLA-A or HLA-B antigens. Results were further supported in experiments using clones (Fig 4) . As shown, cytotoxicity of the clones (from UPN 37) was blocked by anti-MHC class I antigens and anti-HLA-A2 MoAb. In contrast, MoAbs against MHC class I1 were not inhibitory.
Because MiHA-specific TCL responses had been shown to be restricted by class I MHC, the possibility was considered that relative resistance of certain target cells to lysis might be caused by inappropriate expression of the restricting determinants. To test for this, quantitative radioimmunometric measurements of class I or class I1 MHC antigen densities were performed on a panel of hematopoietic and nonhematopoietic targets. Results are shown in Table 4 . Quantitative expression of MHC antigens clearly differed among the various cells analyzed, showing high MHC antigen expression on T blasts and lymphoblastoid cell lines and low or absent on leukemic cells and resting K (Table 4) . Considering the enormous differences in size of K and PHA blasts or lymphoblastoid cell lines, these differences in MHC class I antigen expression were even more pronounced. After incubation of K with rIFN-y using doses up to 1,000 U/mL MHC class I antigen, expression values increased in a dosedependent manner. As discussed in the previous paragraph, For of the test population. No evidence was obtained for restriction of the MiHA-specific TCL response in this panel for a single HLA specificity. This was different in patient UPN 37, in whom the haplotypes HLA-A 3, B 5 and HLA-A 2, B7 were involved. Testing of PHA blasts of 19 unrelated donors with clones derived from this patient strongly suggest that this MiHA-specific TCL response is restricted by HLA-A 2 (Fig 6) . By its capacity to enhance class I MHC antigen expression IFN-y renders K targets susceptible to lysis by MiHA-specijic TCL. As discussed in the previous paragraph, K representing the natural targets for GVHD exhibited a low constitutive expression of class I MHC antigens and also display relative resistance to lysis by MiHA-specific cytotoxic TCL. We tested whether preexposure of K targets to IFN-y would render them susceptible to lysis by TCL. Results shown in Fig 7 indicate that IFN-y, but not IFN-a, renders these cells susceptible to lysis by MiHA-specific TCL. Lysis of IFN-y preincubated cells was again inhibited by anti-class I MHC MoAb (data not shown), demonstrating the crucial role of increased MHC class I antigen expression. To exclude that lysis of K exposed to IFN-y might be due to a toxic effect on K, natural killing experiments were performed. No difference in susceptibility to lysis by NK cells between IFN-y-treated or untreated K was found ( Table 5) . MiHA are expressed on host leukemic cells. In 3 patients suffering from CML, cytotoxic TCL specific for MiHA were used to test the presence of these antigens on host leukemic cells. As shown in Fig 1, leukemic cells were quite resistant to the lytic attack of TCL.
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This effect was studied in more detail in a chromium release assay and leukemia colony inhibition test, using clones from patient UPN 37. In the Cr release assay, leukemic target cells were recognized by clones (specific lysis, 40%; E:T, 25: 1 ; see Fig 2) . The presence of MiHA on host leukemic cells was also confirmed by the leukemia colony inhibition assay. Growth of the patient's tumor cell colonies was drastically inhibited by the clone isolated during GVHD. This effect was host leukemia-specific, because growth of third-party, HLAmismatched leukemia cells was not affected by the clone (Fig  8) . DISCUSSION We demonstrate here that (1) host-specific cytotoxic T lymphocytes are detected exclusively in the PB of patients with acute GVHD after allogeneic BMT between HLA-identical siblings and ( 2 ) their target antigens are simultaneously expressed on several host cell lines, including lymphoblastoid cell lines, PHA blasts, leukemic cells, and K.
Our data, which indicate that successful establishment of MiHA-specific TCL is restricted to patients with extensive methods and immunosuppression used in the prophylaxis of GVHD. Furthermore, timing might play an important role in isolating TCL. In patient UPN 49, TCL were isolated exclusively during GVHD, and not IO days after GVHD had been successfully treated with highdose methylprednisolone. We further investigated the presence of MiHA on different host tissues and the role of the density of the restricting class I MHC elements. The presence of MiHA on hematopoietic cells and K has already been reported by Goulmy and othe r~. '~*~~-~~*~~ We found that MiHA recognized by donor antihost TCL are simultaneously expressed on host lymphoblasts, on host K, and in one case on host leukemia cells and therefore not restricted to a single cell lineage. The presence of MiHA on cells of different tissues, however, did not result in an equal susceptibility of these cells to TCL. The amount MiHA-specific cytotoxic TCL and also displayed MiHA-specific CTLp frequencies of less than 1/300,000. Of the other 4 patients, two developed grade I1 GVHD, gave rise to esof cell killing varied among target cells and paralleled the constitutive expression ofthe restricting class I MHC antigens.
by demWe now expand previous information in tablishment of MiHA-specific weakly cytolytic TCL, but also exhibited MiHA-specific CTL-p frequencies below the detection limit. The last 2 patients presented with grade 111 GVHD, gave rise to highly cytolytic MiHA-specific TCL and clones, and displayed very high frequencies of MiHA-specific CTLp of 1/13,833 and 1/7,933, respectively. In both these cases, CTL-p frequencies were below the detection limit before onset of GVHD. Taken together, our data support the view that extensive GVHD is accompanied by massive enlargement of the MiHA-specific CTL-p pool and that this favors the establishment of specific TCL or clones. The cononstrating that, at least in part, differences in the surface density of the restricting class 1 MHC determinants between hematopoietic and epithelial targets account for this unexpected and so-far unexplained relative resistance of epithelial cells. Data presented here with MiHA-specific class I MHC-restricted TCL thus confirm our previous findings of relative resistance of MHCdisparate K to lysis by MHC-specific TCL.& In this case, too, pretreatment of K with IFN--y enhanced their susceptibility to MHC-specific TCL, and their response was also inhibited by anti-class I MHC antibodies!6
The view of the crucial role of class I MHC expression on tradiction between the present results and those presented by Van Els et a143 might be explained by different detection GVHD target tissues and of IFN--y regulating this key parameter is also supported by recent in vitro and in vivo find- Understanding the role of IFN-y in the pathomechanisms of GVHD has several implications. First of all, it provides an explanation for the frequent association between infections and GVHD.",54,55 Infections trigger the release of cytokines, which in turn can enhance alloreactivity by increasing MHC class I antigen expression on target cellss4 In addition, the role of IFN-y might explain tolerance mechanisms at target level and tissue specificity of GVHD. Local production of IFN-y might induce local G V H D and certain tissues are less inducible to express restricting MHC determinants. This analysis also provides a rationale for using cytokine modulation to prevent GVHD.
Leukemic cells have previously been shown to be susceptible to lysis mediated by MiHA-specific cytotoxic T lymp h o c y t e~.~~ However, in our analysis we found that a clone isolated from a patient after BMT recognized leukemic cells, K, and lymphoblastoid cells from the host. Although our search for graft-versus-leukemia effects mediated by an MiHA-specific clone is so far limited to one case, the data presented clearly demonstrate that clones that lyse K only after pretreatment with IFN-y effectively kill and inhibit growth of native host leukemic cells. This raises the hope that GVHD and antileukemic resistance can be differentiated on the basis of their different cytokine requirements. Obviously, much more data are required to assess the relevance of this observation. Such studies are now in progress at our institution.
